Uterine Cancer
Endometrioid, serous, clear cell, and carcinosarcoma
DefinitionClick to collapse
Endometrial cancer (also known as adenocarcinoma of the endometrium, or more broadly, uterine cancer or carcinoma of the uterine corpus) is a malignant epithelial tumor arising from the endometrial lining of the uterus, the innermost layer of the myometrium. The uterus is a hollow, muscular organ of the female reproductive system, embryologically derived from the Müllerian ducts (paramesonephric ducts). The endometrium is the glandular and stromal tissue lining the uterine cavity, which undergoes cyclic changes under hormonal influence during the menstrual cycle. Anatomically, the uterus is situated in the pelvis, posterior to the bladder and anterior to the rectum. It consists of the fundus (superior portion), the corpus (body), and the cervix (inferior portion). The endometrium can be divided functionally into two layers: the stratum functionalis, which is shed during menstruation, and the deeper basalis, which remains and regenerates the functional layer. Uterine sarcomas are a distinct group of uncommon malignant mesenchymal tumors arising from the connective tissue, smooth muscle, or other non-epithelial components of the uterine wall. They account for approximately 3% of all uterine cancers. The myometrium is the thick middle layer of smooth muscle, and the serosa is the outer peritoneal covering. Sarcomas can originate from the myometrial smooth muscle (leiomyosarcoma), endometrial stromal cells (endometrial stromal sarcoma), or other mesenchymal elements. The NCCN Guidelines encompass both malignant epithelial tumors (carcinomas) and uterine sarcomas, as they require different management strategies (see UN-1, Initial Evaluation). [References: UN-1, Discussion MS-3, UTSARC-A 1]
EpidemiologyClick to collapse
SubtypesClick to collapse
Endometrioid Adenocarcinoma
The most common histologic type of endometrial carcinoma, resembling the normal endometrial glands. It is typically estrogen-dependent and often presents at an early stage with favorable prognosis. Graded from G1 (well-differentiated) to G3 (poorly differentiated).
Serous Carcinoma
A high-grade, aggressive non-endometrioid histologic subtype. It typically arises in older women and has a propensity for early extrauterine spread, even with apparently early-stage disease.
Clear Cell Carcinoma
A non-endometrioid histologic subtype characterized by cells with clear cytoplasm and hobnail or papillary patterns. It is considered a high-risk histology.
Carcinosarcoma
Also known as malignant mixed Müllerian tumor (MMMT). This is a biphasic tumor containing both malignant epithelial (carcinoma) and malignant mesenchymal (sarcoma) components. Per NCCN guidelines, carcinosarcomas are now considered and treated as high-grade endometrial cancers (carcinomas), not uterine sarcomas.
Undifferentiated/Dedifferentiated Carcinoma
Undifferentiated carcinoma shows a lack of recognizable differentiation toward any specific cell line. Dedifferentiated carcinoma consists of a juxtaposition of undifferentiated carcinoma with a well-differentiated endometrioid component.
Low-Grade Endometrial Stromal Sarcoma (ESS)
A mesenchymal tumor composed of cells resembling the endometrial stroma of the proliferative phase. It is characterized by infiltrative growth with tongue-like projections into the myometrium and frequent lymphovascular space invasion (LVSI).
High-Grade Endometrial Stromal Sarcoma
An aggressive ESS variant with distinct genetic rearrangements. Subtypes include YWHAE::NUTM2A/B fusion-positive and BCOR-altered (ZC3H7B::BCOR fusion or BCOR internal tandem duplication).
Uterine Leiomyosarcoma (uLMS)
The most common uterine sarcoma subtype, originating from the smooth muscle of the myometrium. It can be of conventional (spindle cell), epithelioid, or myxoid histologic type.
Müllerian Adenosarcoma
A biphasic tumor with a benign, often metaplastic, epithelial component and an atypical, usually low-grade, mesenchymal component. Sarcomatous overgrowth (SO), defined as sarcoma comprising ≥25% of the tumor volume, indicates a worse prognosis.
Perivascular Epithelioid Cell Tumor (PEComa)
A mesenchymal neoplasm composed of perivascular epithelioid and/or spindled cells that co-express melanocytic and muscle markers.
Inflammatory Myofibroblastic Tumor (IMT)
A spindle cell neoplasm with admixed inflammatory infiltrate. Histologic patterns vary from myxoid hypocellular areas to more compact cellular areas.
Rhabdomyosarcoma (RMS)
An aggressive, heterogeneous group of tumors with skeletal muscle differentiation. Subtypes include embryonal, alveolar, and pleomorphic.
Molecular PathogenesisClick to collapse
Endometrial carcinoma exhibits distinct molecular pathogenesis. The TCGA classification identifies four clinically significant molecular subgroups: 1) POLE-mutated: Characterized by mutations in the exonuclease domain of DNA polymerase epsilon (POLE), often high-grade but with excellent prognosis. Hotspot mutations include P286R and V411L. 2) Microsatellite Instability-High (MSI-H) / Mismatch Repair Deficient (dMMR): Results from defective DNA mismatch repair, often due to MLH1 promoter methylation or germline mutations (Lynch syndrome). Associated with intermediate prognosis and potential sensitivity to immune checkpoint inhibitors. 3) No Specific Molecular Profile (NSMP): Corresponds to copy-number-low/wild-type p53 tumors. Typically endometrioid histology, estrogen-dependent, with favorable prognosis. 4) p53 Aberrant: Characterized by TP53 mutations, associated with serous histology, high copy-number alterations, and the worst prognosis. Requires multimodality treatment. Molecular testing for POLE mutations, MMR/MSI status, and p53 IHC is recommended to complement morphologic assessment (ENDO-A). For uterine sarcomas, molecular profiling is key for classification: - Low-grade ESS: Associated with JAZF1::SUZ12, JAZF1::PHF1, EPC1::PHF1 fusions. - High-grade ESS: YWHAE::NUTM2 fusions, ZC3H7B::BCOR fusions, or BCOR internal tandem duplication. - Leiomyosarcoma: Complex karyotypes; commonly altered genes include TP53, ATRX, RB1, PTEN. - PEComa: TSC1/TSC2 mutations, TFE3 fusions. - IMT: ALK rearrangements. - RMS: DICER1 mutations (embryonal), FOXO1 fusions (alveolar). Comprehensive genomic profiling is encouraged in metastatic disease to identify targets like NTRK, RET, and TMB (UTSARC-A). [References: ENDO-A, UTSARC-A, Discussion MS-4, MS-32-34]
Risk FactorsClick to collapse
Unopposed Estrogen Exposure
Increased levels of endogenous or exogenous estrogen without opposing progesterone is a primary risk factor. This includes obesity (peripheral conversion in adipose tissue), chronic anovulation, polycystic ovarian syndrome (PCOS), and exogenous estrogen therapy without progestin.
Obesity
A major risk factor. Fat cells convert androgens to estrogens via aromatase. The incidence of endometrial cancer increases with body mass index (BMI).
Diabetes Mellitus
An independent risk factor, likely related to hyperinsulinemia, which may promote endometrial proliferation.
Hypertension
Often associated with obesity and diabetes, and is an independent risk factor.
Lynch Syndrome
Hereditary nonpolyposis colorectal cancer (HNPCC) syndrome, caused by germline mutations in mismatch repair genes (MLH1, MSH2, MSH6, PMS2). Carriers have a lifetime risk of endometrial cancer of up to 60%. Endometrial cancer may be the first manifestation.
Tamoxifen Use
Selective estrogen receptor modulator (SERM) used for breast cancer treatment and prevention. It has agonist effects on the endometrium, increasing the risk of endometrial hyperplasia and cancer with prolonged use (typically >2 years).
Nulliparity
Never having been pregnant. Pregnancy has a protective effect due to progestin dominance.
Early Menarche / Late Menopause
Prolonged exposure to cyclic estrogen without the protective effect of progesterone from ovulation.
Age
The risk increases with age, with most cases diagnosed after age 55.
Endometrial Hyperplasia with Atypia
Atypical endometrial hyperplasia is a direct precursor lesion for endometrioid adenocarcinoma.
Family History
A family history of endometrial, ovarian, or colorectal cancer, even in the absence of known Lynch syndrome, may increase risk.
Clinical FeaturesClick to collapse
Typical Presentation
The classic presentation of endometrial carcinoma is abnormal uterine bleeding, most commonly postmenopausal bleeding (vaginal bleeding after menopause), which prompts investigation. In premenopausal women, it may manifest as menorrhagia or intermenstrual bleeding. Patients may also present with pelvic pain or pressure, though this is less common. For uterine sarcomas, presentation often includes a rapidly enlarging pelvic mass, which may be painful, or abnormal bleeding. Adenosarcomas may present as a polypoid mass protruding through the cervix.
Symptoms
Abnormal uterine bleeding
The most common symptom, occurring in about 90% of patients. This includes postmenopausal bleeding, metrorrhagia, or menorrhagia.
Pelvic pain or pressure
May be present due to tumor size or local spread.
Pelvic mass
More common in sarcomas, which may present as a rapidly growing mass.
Vaginal discharge
May be serosanguinous or purulent.
Signs
Uterine enlargement
On pelvic examination, the uterus may be palpably enlarged or irregular, especially with larger tumors or sarcomas.
Cervical mass or bleeding
With cervical involvement, a friable mass may be seen or palpated.
Adnexal mass
May indicate ovarian or tubal involvement, or metastatic disease.
Red FlagsClick to collapse
Postmenopausal vaginal bleeding
Premenopausal abnormal uterine bleeding not responsive to medical management
Rapidly enlarging pelvic mass
Pelvic pain with a palpable adnexal or uterine mass
Abnormal cervical cytology suggesting a high-grade lesion
Ascites or evidence of peritoneal disease
Symptoms suggestive of metastatic disease (e.g., hemoptysis, bone pain, neurological deficits)
InvestigationsClick to collapse
Diagnostic
Endometrial biopsy or dilation and curettage (D&C)
Direct sampling of the endometrium to obtain histologic diagnosis.
Hysteroscopy
Direct visualization of the uterine cavity and targeted biopsy of lesions.
Expert pathology review
Crucial for accurate histologic subtyping and grading, especially for high-risk or unusual histologies.
Staging
Pelvic MRI (with and without contrast)
Best imaging for local staging: depth of myometrial invasion, cervical stromal involvement, and local extent.
Chest/abdomen/pelvis CT (with contrast)
Evaluates for metastatic disease, particularly in high-grade histologies or advanced stage.
FDG-PET/CT
May help in evaluating equivocal findings on other imaging or to assess for metastatic disease.
Chest X-ray
Initial screening for pulmonary metastases.
Pelvic ultrasound
May be used if uterine size is unclear on exam.
Biomarkers
Immunohistochemistry (IHC) for mismatch repair (MMR) proteins (MLH1, PMS2, MSH2, MSH6) or microsatellite instability (MSI) testing
Identifies dMMR/MSI-H tumors, which have prognostic implications and predict response to immunotherapy.
POLE mutation analysis
Identifies POLE-mutated tumors, which are often high-grade but have an excellent prognosis.
p53 immunohistochemistry
Surrogate for TP53 mutation, identifying the most aggressive molecular subtype (p53 aberrant).
HER2 IHC (with reflex to FISH if equivocal)
Required for p53-aberrant carcinomas (e.g., serous) and all metastatic/recurrent disease to guide trastuzumab-based therapy.
NTRK gene fusion testing
Identifies tumors with NTRK fusions, which respond to TRK inhibitors.
RET gene fusion testing
Identifies tumors with RET fusions, which respond to RET inhibitors.
Tumor mutational burden (TMB) testing
High TMB (≥10 mut/Mb) identifies tumors likely to respond to pembrolizumab.
Estrogen receptor (ER) and progesterone receptor (PR) testing
May guide hormonal therapy options in recurrent/metastatic disease.
StagingClick to collapse
All staging in this guideline is based on the 2009 FIGO surgical staging system and the AJCC Cancer Staging Manual, 8th Edition.
T Categories
| Stage | Description |
|---|---|
| TX | Primary tumor cannot be assessed. |
| T0 | No evidence of primary tumor. |
| T1 | Tumor confined to the corpus uteri, including endocervical glandular involvement. |
| T1a | Tumor limited to the endometrium or invading less than half the myometrium. |
| T1b | Tumor invading one half or more of the myometrium. |
| T2 | Tumor invading the stromal connective tissue of the cervix but not extending beyond the uterus. Does NOT include endocervical glandular involvement. |
| T3 | Tumor involving serosa, adnexa, vagina, or parametrium. |
| T3a | Tumor involving the serosa and/or adnexa (direct extension or metastasis). |
| T3b | Vaginal involvement (direct extension or metastasis) or parametrial involvement. |
| T4 | Tumor invading the bladder mucosa and/or bowel mucosa (bullous edema is not sufficient to classify a tumor as T4). |
N Categories
| Stage | Description |
|---|---|
| NX | Regional lymph nodes cannot be assessed. |
| N0 | No regional lymph node metastasis. |
| N0(i+) | Isolated tumor cells in regional lymph node(s) no greater than 0.2 mm. |
| N1 | Regional lymph node metastasis to pelvic lymph nodes. |
| N1mi | Regional lymph node metastasis (greater than 0.2 mm but not greater than 2.0 mm in diameter) to pelvic lymph nodes. |
| N1a | Regional lymph node metastasis (greater than 2.0 mm in diameter) to pelvic lymph nodes. |
| N2 | Regional lymph node metastasis to para-aortic lymph nodes, with or without positive pelvic lymph nodes. |
| N2mi | Regional lymph node metastasis (greater than 0.2 mm but not greater than 2.0 mm in diameter) to para-aortic lymph nodes, with or without positive pelvic lymph nodes. |
| N2a | Regional lymph node metastasis (greater than 2.0 mm in diameter) to para-aortic lymph nodes, with or without positive pelvic lymph nodes. |
M Categories
| Stage | Description |
|---|---|
| M0 | No distant metastasis. |
| M1 | Distant metastasis (includes metastasis to inguinal lymph nodes, intraperitoneal disease, lung, liver, or bone). It excludes metastasis to pelvic or para-aortic lymph nodes, vagina, uterine serosa, or adnexa. |
Stage Groupings
| Group | Criteria | Clinical Meaning | Five Yr Survival | Treatment Intent |
|---|---|---|---|---|
| Stage I | T1, N0, M0 | Tumor confined to the corpus uteri. | Not explicitly stated in the source text for this group alone; varies by histology and grade. | Curative. |
| Stage IA | T1a, N0, M0 | Tumor limited to the endometrium or invading less than half the myometrium. | Excellent for low-grade endometrioid histology. | Curative. |
| Stage IB | T1b, N0, M0 | Tumor invading one half or more of the myometrium. | Varies by grade; worse for high-grade histologies. | Curative. |
| Stage II | T2, N0, M0 | Tumor invading cervical stroma but not beyond uterus. | Intermediate; influenced by grade and other factors. | Curative. |
| Stage III | T3, N0, M0 | Tumor involving serosa, adnexa, vagina, or parametrium. | Poor for high-grade histologies; better for low-grade endometrioid. | Curative with multimodality therapy. |
| Stage IIIA | T3a, N0, M0 | Tumor involving serosa and/or adnexa. | Variable. | Curative. |
| Stage IIIB | T3b, N0, M0 | Vaginal or parametrial involvement. | Variable. | Curative. |
| Stage IIIC1 | T1-T3, N1/N1mi/N1a, M0 | Regional lymph node metastasis to pelvic lymph nodes. | Significantly worse than node-negative disease. | Curative with systemic therapy ± radiation. |
| Stage IIIC2 | T1-T3, N2/N2mi/N2a, M0 | Regional lymph node metastasis to para-aortic lymph nodes, with or without positive pelvic nodes. | Worse than IIIC1. | Curative with systemic therapy ± radiation. |
| Stage IVA | T4, Any N, M0 | Tumor invading bladder and/or bowel mucosa. | Poor. | Curative with multimodality therapy, if resectable. |
| Stage IVB | Any T, Any N, M1 | Distant metastasis. | Very poor for most histologies. | Palliative; systemic therapy. |
Staging Pearls
- Positive peritoneal cytology does not affect the FIGO stage but is an adverse risk factor.
- Isolated tumor cells (ITCs) in lymph nodes are staged N0(i+) and do not upstage patients, but may influence adjuvant therapy discussions.
- The presence of sarcomatous overgrowth (SO) in adenosarcoma is a poor prognostic factor and influences stage-grouping for sarcoma staging.
- Molecular subtype (POLE-mutated, MSI-H, p53-aberrant, NSMP) provides additional prognostic information beyond anatomic stage.
- For uterine sarcomas, a separate staging system (AJCC 8th Edition) is used, which is based on tumor size and extent rather than depth of invasion.
Management PrinciplesClick to collapse
The management of uterine neoplasms is based on a multidisciplinary approach, integrating surgery, radiation therapy (RT), systemic therapy, and molecular profiling. Treatment intent varies from curative for localized disease to palliative for advanced or recurrent disease. The guidelines emphasize the importance of expert pathology review, molecular analysis (including POLE mutations, MMR/MSI, p53, HER2, ER/PR, NTRK, RET, and TMB testing), and individualized treatment based on histologic type, stage, and risk factors. Surgical staging is recommended for most patients, with minimally invasive surgery preferred when feasible. Adjuvant therapy decisions are guided by pathologic findings, and molecular subtypes may influence therapy escalation or de-escalation. Clinical trial enrollment is strongly encouraged.
Curative
Patients with localized or regionally confined disease suitable for surgery with or without adjuvant therapy.
Primary treatment typically involves surgical resection (TH/BSO with staging) followed by risk-adapted adjuvant therapy (RT, systemic therapy, or observation). For medically inoperable patients, definitive RT with or without brachytherapy is an alternative. Fertility-sparing options are considered for select patients with low-risk disease.
Palliative
Patients with advanced, recurrent, or metastatic disease not amenable to curative surgery.
Systemic therapy (chemotherapy, immunotherapy, targeted therapy, or hormonal therapy) is the mainstay, often combined with RT for symptom control. Local therapies like SBRT or ablation may be used for oligometastatic disease. Best supportive care is emphasized for patients with poor performance status.
Multidisciplinary expertise is recommended for all patients, involving gynecologic oncologists for surgical management, pathologists for histologic and molecular analysis, radiologists for imaging, radiation oncologists for RT planning, and medical oncologists for systemic therapy. For uterine sarcomas, referral to a center specializing in mesenchymal tumors is advised.
Performance status is considered in surgical eligibility and treatment intensity. Patients with good performance status (e.g., ECOG 0-1) are candidates for aggressive multimodality therapy, while those with poor performance status may receive reduced-intensity or palliative approaches. Detailed guidelines are referenced in the NCCN Guidelines for Older Adult Oncology for age-related considerations.
Management PathwaysClick to collapse
Branching: Histologic grade, Depth of myometrial invasion, LVSI, Age, Molecular profile
Branching: Cervical biopsy results, Resectability, Performance status
Branching: Imaging findings, Resectability, Histology
Branching: FIGO stage, Histologic grade, LVSI, Age, Molecular profile
Branching: Intraoperative findings, Imaging results, Pathologic risk factors
Branching: Grade, Stage, Response to therapy, Fertility goals
Branching: Initial stage, Histology, Risk factors
Branching: Prior RT, Disease site, Resectability
Branching: Stage, Residual disease, Molecular profile (HER2, p53)
Branching: Stage, Residual disease, Molecular profile
Branching: Stage, Resectability
Branching: Stage, Resectability, HER2 status
Branching: Histologic type, Residual disease, Stage
Branching: Disease extent, Resectability, Histologic subtype
Branching: Stage, Ovarian status, ER/PR status
Branching: Stage, Residual disease
Branching: Stage, Grade, Molecular profile (NTRK, ALK, TMB, BRCA)
Branching: Histology, Grade, Initial stage
Branching: Site of recurrence, Prior RT, Resectability, Histology
Pretreatment EvaluationClick to collapse
Initial Evaluation
Pathology
Functional Assessment
Consultation
SurgeryClick to collapse
Primary treatment for medically operable patients with uterine neoplasms. Surgical staging provides critical prognostic information to guide adjuvant therapy.
TH/BSO with surgical staging is the standard for apparent uterine-confined disease unless fertility-sparing is desired.
Minimally invasive surgery (laparoscopic, robotic) is preferred when technically feasible due to lower morbidity without compromise in oncologic outcome.
Endometrial carcinoma should be removed en bloc; intraperitoneal morcellation or fragmentation should be avoided.
Lymph node assessment includes SLN mapping (preferred) or pelvic ± para-aortic lymphadenectomy. SLN algorithm should be adhered to for accurate staging.
For stage II disease, radical hysterectomy should only be performed if needed to obtain negative margins.
Ovarian preservation may be safe in select premenopausal patients with stage IA G1 endometrioid cancer, normal ovaries, no family history of ovarian cancer or Lynch syndrome, and absence of p53 abnormality, MMR deficiency, LVSI, and positive cytology. Salpingectomy recommended.
For uterine sarcomas, expert pathology review is critical; morcellation contraindicated. Lymphadenectomy controversial and not routinely recommended unless clinical suspicion.
Oophorectomy individualized for reproductive-age patients with uterine sarcomas; favor BSO if ER/PR positive.
Procedures
Total Hysterectomy (TH) with Bilateral Salpingo-Oophorectomy (BSO)
Primary treatment for uterine-confined endometrial carcinoma and most uterine sarcomas.
Radical Hysterectomy (RH)
Stage II disease with cervical stromal involvement to obtain negative margins.
Sentinel Lymph Node (SLN) Mapping and Biopsy
Apparent uterine-confined endometrial carcinoma for staging.
Surgical Staging/Debulking for Advanced Disease
Suspected extrauterine disease (abdominal/pelvic-confined) with goal of no measurable residual disease.
Metastasectomy for Oligometastatic Disease
Isolated metastases in uterine sarcoma or endometrial carcinoma with controlled primary.
Radiation TherapyClick to collapse
Used for adjuvant treatment to improve locoregional control, definitive treatment for medically inoperable patients, and palliation for recurrent/metastatic disease.
Principles
- RT is directed at sites of known or suspected tumor involvement and may include EBRT and/or brachytherapy.
- Imaging required to assess locoregional extent and rule out distant metastases before RT.
- EBRT typically targets pelvis with or without para-aortic region. Brachytherapy delivered to intact uterus preoperatively/definitively or to vagina post-hysterectomy.
- Whole abdominal radiotherapy is not considered tumor-directed RT and is no longer recommended due to toxicity.
- Chemoradiation can be given concurrently or sequentially.
- For uterine sarcomas, adjuvant RT reduces local recurrence but no consistent OS benefit; role controversial.
Dose Frameworks
| Name | Total Dose | Dose Per Fraction | Fractions | Schedule | Indication |
|---|---|---|---|---|---|
| Adjuvant Pelvic EBRT | 45–50 Gy | 1.8–2.0 Gy | 25–28 | Daily, 5 days per week. | Microscopic disease in pelvis and para-aortic nodes for high-risk endometrial carcinoma or uterine sarcomas. |
| Boost for Gross Residual Disease | 60–70 Gy | 1.8–2.0 Gy | Additional 5–10 | Sequential after pelvic EBRT. | Postoperative gross residual disease or gross nodal disease (boost to 60–65 Gy). |
| Neoadjuvant Radiation | 45–50 Gy ± HDR brachytherapy boost to total EQD2 75–80 Gy | EBRT: 1.8–2.0 Gy; HDR: 5–7 Gy per fraction | EBRT: 25–28; HDR: 1–2 insertions | Sequential. | To minimize positive margins at hysterectomy for cervical involvement or locally advanced disease. |
| Postoperative Vaginal Brachytherapy Alone | 30–35 Gy EQD2 | 5.5–7 Gy | 3–5 | Weekly or twice weekly. | Adjuvant for low-intermediate risk endometrial carcinoma (e.g., Stage IA G1-2, Stage IB G1). |
| Brachytherapy Boost to EBRT | 10–18 Gy EQD2 | 4–6 Gy | 2–3 | Concurrent or sequential with EBRT. | Boost to vaginal cuff after hysterectomy for higher risk features. |
| Definitive Brachytherapy for Medically Inoperable Uterine Cancer | EQD2 D90 ≥48 Gy (brachytherapy alone) or ≥65 Gy (combined EBRT + brachytherapy); GTV target ≥80 Gy with MRI guidance. | Individualized based on fractionation. | Multiple | Individualized. | Medically inoperable uterine-confined carcinoma. |
Approaches
| Name | Dose Fractionation | Concurrent Chemotherapy | Indication | Key Trial | Toxicities |
|---|---|---|---|---|---|
| Intensity-Modulated Radiation Therapy (IMRT) | As per dose frameworks above. | Cisplatin-based concurrent chemoradiation for high-risk disease (category 1 for some histologies). | Pelvic and para-aortic RT for endometrial carcinoma and uterine sarcomas; preferred to minimize toxicity. | PORTEC-3, GOG 258, RTOG 9708. | Diarrhea, bowel symptoms, fatigue, secondary malignancies (long-term). |
| High-Dose-Rate (HDR) Brachytherapy | As per dose frameworks above. | Can be interdigitated with chemotherapy for carcinosarcoma. | Adjuvant vaginal brachytherapy, definitive treatment for medically inoperable disease. | PORTEC-2, Aalders trial. | Vaginal stenosis, bleeding, urinary symptoms. |
| Stereotactic Body Radiation Therapy (SBRT) | 1–5 fractions of ablative doses (e.g., 30–50 Gy in 1–5 fractions). | Not typically concurrent. | Oligometastatic disease (1–5 metastatic lesions) if primary cancer controlled. | SABR-COMET. | Site-specific (e.g., pneumonitis for lung, hepatotoxicity for liver). |
Systemic TherapyClick to collapse
Systemic therapy is used in adjuvant, primary, and recurrent/metastatic settings. Regimens include chemotherapy, immunotherapy, targeted therapy, and hormonal therapy. Choice depends on histology, stage, molecular profile (MSI-H/dMMR, HER2, NTRK, RET, TMB, BRCA, CDK4), and prior treatment. Clinical trial enrollment strongly encouraged.
Key Regimens
Treatment Response AssessmentClick to collapse
Title
Assessment of Treatment Response and Monitoring
Timing
Response assessed during and after primary or adjuvant therapy; surveillance per guidelines.
Response Logic
-
For patients receiving systemic therapy, response assessed using imaging (CT, MRI) and clinical assessment per RECIST criteria.
-
For fertility-sparing therapy, endometrial evaluation every 3–6 months (hysteroscopy, biopsy, D&C) to assess response; complete response defined as no disease on sampling.
-
For uterine sarcomas, imaging surveillance to assess for recurrence or metastatic disease.
-
Molecular response not routinely assessed; clinical correlation essential.
Imaging Recommendations
-
During treatment: imaging as clinically indicated based on symptoms or to assess response to neoadjuvant therapy.
-
Post-treatment: surveillance imaging per histology and stage (see ENDO-9, UTSARC-4).
-
For suspected recurrence: CT abdomen/pelvis and/or chest CT based on symptoms; consider FDG-PET/CT or MRI in select patients.
Biopsy Or Salvage Logic
-
For suspected recurrence, biopsy may confirm histology and guide therapy.
-
For locoregional recurrence, salvage options include surgery, RT, or systemic therapy based on prior treatment and resectability.
-
For distant metastases, biopsy may be performed to confirm diagnosis or for molecular testing (e.g., HER2, NTRK, RET).
-
For persistent disease on fertility-sparing therapy, salvage includes TH/BSO with staging.
SurveillanceClick to collapse
Clinical Follow Up Schedule
- Physical exam (including pelvic exam) every 3-6 months for 2-3 years, then every 6-12 months for up to year 5, then annually [20].
- For uterine sarcoma: Consider H&P every 3-4 months for 2-3 years, then every 6-12 months [21].
- Symptom assessment for potential recurrence (bleeding, pain, weight loss, respiratory symptoms) [20].
Imaging Strategy
- Imaging should be guided by symptoms and clinical suspicion, not performed routinely in asymptomatic patients [20].
- For endometrial cancer: Consider chest imaging if symptoms or high-risk features; imaging as indicated for suspected recurrence [22].
- For uterine sarcoma: Chest/abdomen/pelvis CT every 3-6 months for 3 years, then every 6-12 months for 2 years; optional imaging beyond 5 years depending on histology and stage [21].
- FDG-PET/CT may be considered to clarify ambiguous findings [22].
Laboratory Monitoring
- CA-125 if initially elevated or for serous histology to monitor response [20].
- Routine tumor markers are not recommended for all patients [20].
Supportive Follow Up
- Health maintenance: blood pressure, breast exam, mammography, stool guaiac, immunizations as appropriate [18].
- Counseling on lifestyle: exercise, smoking cessation, nutrition, and weight management [18].
- Assessment of late effects of treatment and referral to specialists (e.g., pelvic floor therapy, sexual health, psychotherapy) [18].
- Survivorship care plan summarizing treatment and follow-up recommendations [18].
ComplicationsClick to collapse
Disease-Related
| Complication | Management |
|---|---|
| Vaginal bleeding | Evaluation with endometrial biopsy or D&C; may be the initial presenting symptom leading to diagnosis. |
| Pelvic pain or mass | Imaging and clinical evaluation; may indicate advanced or recurrent disease. |
| Metastatic disease (e.g., to lung, liver, bone, peritoneum) | Systemic therapy, local therapy (surgery, radiation) for isolated metastases, or palliative care. |
Supportive CareClick to collapse
Supportive care is integral to managing patients with uterine neoplasms, addressing both disease-related and treatment-related toxicities. It includes symptom management, psychosocial support, and survivorship care [18].
Nutritional assessment and counseling are recommended to manage weight changes, especially in patients with obesity, a risk factor for endometrial cancer. Weight management and lifestyle modification are encouraged [18].
Antiemetic prophylaxis based on the emetogenic potential of chemotherapy regimens (e.g., high emetogenic risk for cisplatin, moderate for carboplatin/paclitaxel) [12]. Refer to NCCN Guidelines for Antiemesis.
Granulocyte colony-stimulating factor (G-CSF) support may be considered for chemotherapy regimens with a high risk of febrile neutropenia (e.g., >20%) [12].
Venous thromboembolism (VTE) prophylaxis is recommended for patients undergoing major pelvic surgery and may be considered for those receiving chemotherapy, especially with bevacizumab [15,17].
Pain assessment and management using WHO analgesic ladder; may include NSAIDs, opioids, and adjuvant agents. Referral to pain specialist as needed.
Psychosocial effects may include depression, anxiety, fear of recurrence, financial concerns, and issues with sexuality and intimacy. Referral to psychotherapy, support groups, and financial counseling is recommended [18].
Dental evaluation prior to radiation therapy to the pelvis; management of oral complications from chemotherapy (mucositis, xerostomia).
PrognosisClick to collapse
The prognosis for uterine neoplasms is highly variable depending on histology, stage, grade, and molecular profile. Endometrial carcinoma is the fourth most common female genital tract malignancy in the US, with an estimated 69,120 new cases and 13,860 deaths in 2025 [1]. Uterine sarcomas are uncommon, accounting for about 3% of uterine cancers [2,3]. Mortality rates for uterine cancer have increased more rapidly than incidence, possibly due to rising rates of advanced-stage disease and high-risk histologies [4].
By Stage
| Stage | Five Yr Survival | Context |
|---|---|---|
| Local (confined to uterus) | ~67% of cases | SEER data; survival is increased in patients who are younger, have early-stage disease, and have lower-grade disease [5]. |
| Regional (spread to regional lymph nodes) | ~21% of cases | Nodal involvement is a major adverse prognostic factor [6]. |
| Distant (metastatic) | ~8% of cases | Distant disease has a poor prognosis; 5-year survival is significantly reduced [5]. |
Prognostic Factors
- Age (older age is a poor prognostic factor) [4,5]
- Histologic grade (higher grade indicates worse prognosis) [4]
- Myometrial invasion depth (deeper invasion is associated with higher risk) [7]
- Lymphovascular space invasion (LVSI), especially substantial LVSI [6,7]
- Tumor size [4,6]
- Cervical stromal involvement [6]
- Lymph node metastasis [6]
- Histologic subtype (e.g., serous, clear cell, carcinosarcoma, undifferentiated) [8]
- Molecular profile (POLE-mutated has excellent prognosis; p53-aberrant has poor prognosis) [9,10]
- Presence of peritoneal cytology (its independent prognostic value is questioned) [11]
Follow UpClick to collapse
Post Curative Treatment
After completing primary treatment, patients enter a surveillance phase. The goal is to detect recurrence early when curative salvage therapy may be possible. Surveillance includes regular history and physical exam, symptom evaluation, and selected imaging [20].
Surveillance Rationale
Intensive surveillance has not been shown to improve overall survival in endometrial cancer, but it provides psychosocial reassurance and allows for early detection of recurrences, which are often symptomatic [20]. Most recurrences occur within the first 3 years after treatment.
Late Effects Screening
- Screening for osteoporosis, especially after bilateral salpingo-oophorectomy (BSO) or pelvic radiation [18]
- Assessment for sexual dysfunction, vaginal stenosis, and vaginal dryness [18]
- Evaluation for lymphedema after lymphadenectomy [18]
- Monitoring for secondary malignancies related to prior radiation [19]
- Assessment of cardiovascular risk factors and metabolic syndrome, particularly in patients with obesity [18]
Recurrence Patterns
Most recurrences of endometrial cancer are vaginal or pelvic (locoregional), but distant metastases (e.g., to lung, abdomen) also occur. For uterine sarcomas, especially leiomyosarcoma, hematogenous spread to the lungs is common [21].
Key TrialsClick to collapse
| Acronym | Full Name | Year | N | Intervention | Comparator | Population | Primary Endpoint | Key Result | Secondary Outcomes | Practice Change | Journal |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NRG-GY018 | Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer | 2023 | 816 | Carboplatin/paclitaxel + pembrolizumab | Carboplatin/paclitaxel + placebo | Stage III or IVA endometrial carcinoma with measurable disease, or stage IVB or recurrent disease, any histologic subtype except carcinosarcoma. | Progression-free survival (PFS) | PFS was 74% vs. 38% in the dMMR cohort (HR, 0.30; P<.001). In pMMR tumors, median PFS was 13.1 vs. 8.7 months (HR, 0.54; P<.001) [26]. | Overall survival (OS) data pending. | Established pembrolizumab + carboplatin/paclitaxel as a preferred first-line regimen for advanced/recurrent endometrial cancer, except carcinosarcoma. | New England Journal of Medicine |
| RUBY | Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer | 2023 | 494 | Dostarlimab + carboplatin/paclitaxel | Placebo + carboplatin/paclitaxel | Stage III or IV or recurrent endometrial cancer, all histologies. | PFS | PFS was 36.1% vs. 18.1% at 24 months (HR, 0.64; P<.001). OS was 71.3% vs. 56% (HR, 0.64; P=.002) [27]. | OS benefit in the overall population and in dMMR/MSI-H subgroup. | Established dostarlimab + carboplatin/paclitaxel as a preferred first-line regimen for advanced/recurrent endometrial cancer. | New England Journal of Medicine |
| DUO-E | Durvalumab Plus Carboplatin/Paclitaxel with or without Olaparib in Advanced Endometrial Cancer | 2024 | 655 | Carboplatin/paclitaxel + durvalumab ± maintenance durvalumab ± olaparib | Carboplatin/paclitaxel + placebo | Advanced or recurrent endometrial cancer. | PFS | PFS benefit for durvalumab (HR, 0.71; P=.003) and durvalumab+olaparib (HR, 0.55; P<.0001) vs. control. Greatest benefit in dMMR subgroup [14]. | PFS in pMMR subgroup: HR 0.57 for durvalumab+olaparib vs. control. | Carboplatin/paclitaxel + durvalumab is a preferred first-line regimen for dMMR tumors only. | Journal of Clinical Oncology |
| PORTEC-3 | Adjuvant Chemoradiotherapy versus Radiotherapy Alone for High-Risk Endometrial Cancer | 2019 | 686 | Chemoradiation (cisplatin/paclitaxel + EBRT + vaginal brachytherapy) | EBRT alone | High-risk endometrial cancer (stage I grade 3 with deep invasion/LVSI, stage II, stage III, or any serous/clear cell). | Failure-free survival (FFS) | 5-year FFS was 76.5% vs. 69.1% (HR, 0.70; P=.016). 5-year OS was 81.4% vs. 76.1% (HR, 0.70; P=.034) [36]. | Toxicity, quality of life. | Established adjuvant chemoradiation as standard for high-risk endometrial cancer. | Lancet Oncology |
| KEYNOTE-775 | Lenvatinib plus Pembrolizumab versus Chemotherapy in Advanced Endometrial Cancer | 2022 | 827 | Lenvatinib + pembrolizumab | Chemotherapy (doxorubicin or paclitaxel) | pMMR (MSI-stable) advanced endometrial cancer after prior systemic therapy. | PFS and OS | Median PFS: 7.2 vs. 3.8 months (HR, 0.56; P<.001). Median OS: 18.3 vs. 11.4 months (HR, 0.62; P<.001) [25]. | Response rate, duration of response. | Established lenvatinib/pembrolizumab as a preferred second-line option for pMMR tumors. | New England Journal of Medicine |
| LMS-04 | Doxorubicin alone versus Doxorubicin with Trabectedin as First-Line Therapy for Metastatic or Unresectable Leiomyosarcoma | 2022 | 150 | Doxorubicin + trabectedin | Doxorubicin alone | Metastatic or unresectable leiomyosarcoma (soft tissue or uterine). | PFS | Median PFS: 12.2 vs. 6.2 months (HR, 0.41; P<.0001) [29]. | OS, response rate. | Established doxorubicin/trabectedin as a preferred first-line regimen for advanced LMS. | Lancet Oncology |
Clinical PearlsClick to collapse
- Pearl 1: Molecular classification (POLE-mutated, dMMR, NSMP, p53-aberrant) is now central to prognosis and may guide therapy in endometrial cancer [9,10].
- Pearl 2: Ovarian preservation may be safe in select premenopausal patients with stage IA G1 endometrioid cancer, normal-appearing ovaries, no family history of ovarian cancer or Lynch syndrome, and absence of p53 abnormality, dMMR, LVSI, and positive cytology [31].
- Pearl 3: Sentinel lymph node (SLN) mapping with ultrastaging is the preferred alternative to full lymphadenectomy for staging apparent uterine-confined endometrial cancer [32].
- Pearl 4: Minimally invasive surgery (laparoscopy or robotic) is preferred for staging when feasible due to lower perioperative complications without compromising oncologic outcomes [17].
- Pearl 5: Carcinosarcoma is treated as a high-grade endometrial carcinoma, not a sarcoma [8].
- Pearl 6: In recurrent endometrial cancer, lenvatinib/pembrolizumab is a category 1 preferred option for pMMR tumors after prior platinum-based therapy [25].
- Pearl 7: For dMMR/MSI-H recurrent endometrial cancer, pembrolizumab or dostarlimab are highly effective and preferred [26,27].
- Pearl 8: Morcellation should be avoided when sarcoma is suspected, as it can lead to peritoneal spread [21].